Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks
Publication
, Journal Article
Farnier, M; Colhoun, HM; Sasiela, WJ; Edelberg, J; Asset, G; Robinson, JG
Published in: Atherosclerosis
September 2016
Duke Scholars
Published In
Atherosclerosis
DOI
ISSN
0021-9150
Publication Date
September 2016
Volume
252
Start / End Page
e254 / e254
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Farnier, M., Colhoun, H. M., Sasiela, W. J., Edelberg, J., Asset, G., & Robinson, J. G. (2016). Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. Atherosclerosis, 252, e254–e254. https://doi.org/10.1016/j.atherosclerosis.2016.07.070
Farnier, M., H. M. Colhoun, W. J. Sasiela, J. Edelberg, G. Asset, and J. G. Robinson. “Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks.” Atherosclerosis 252 (September 2016): e254–e254. https://doi.org/10.1016/j.atherosclerosis.2016.07.070.
Farnier M, Colhoun HM, Sasiela WJ, Edelberg J, Asset G, Robinson JG. Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. Atherosclerosis. 2016 Sep;252:e254–e254.
Farnier, M., et al. “Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks.” Atherosclerosis, vol. 252, Elsevier BV, Sept. 2016, pp. e254–e254. Crossref, doi:10.1016/j.atherosclerosis.2016.07.070.
Farnier M, Colhoun HM, Sasiela WJ, Edelberg J, Asset G, Robinson JG. Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. Atherosclerosis. Elsevier BV; 2016 Sep;252:e254–e254.
Published In
Atherosclerosis
DOI
ISSN
0021-9150
Publication Date
September 2016
Volume
252
Start / End Page
e254 / e254
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology